According to the Leverkusen-based company, the Bayer drug Finerenon has achieved a statistically significant and clinically relevant result in a Phase III study in certain heart failure patients.

"We are very pleased with the positive results of the FINEARTS-HF study," said Christian Rommel, Head of Research and Development at Bayer's Pharmaceuticals Division: "As treatment options for patients with this common form of heart failure with mildly reduced or preserved ejection fraction are currently limited, this news is extremely important for patients and physicians." Patients with at least 40 percent left ventricular ejection fraction could soon make up the majority of patients hospitalized with heart failure. Bayer is committed to "making finerenone available to appropriate patients as soon as possible".

(Report by Matthias Inverardi, edited by Olaf Brenner. If you have any questions, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and the economy) or frankfurt.newsroom@thomsonreuters.com (for companies and markets).)